Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sildenafil
Drug ID BADD_D02018
Description In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment for angina - or chest pain associated with inadequate blood flow to the heart - before being serendipitously indicated for treating erectile dysfunction in the late 1980s [A175732]. Nevertheless, it is because of this mechanism that sildenafil is also indicated for treating pulmonary arterial hypertension but is also additionally notorious for interacting with various anti-anginal or anti-hypertensive agents to develop potentially rapid, excessive, and/or fatal hypotensive crises [A175579, A175582, A175654]. Regardless, sildenafil, among a variety of other similar or related PDE5 inhibitors, has become a common and effective treatment for erectile dysfunction and since its formal approval for medical use in the public in 1998 [A175732], continues to see millions of prescriptions written for it internationally. Although the medication has historically been most popularly recognized as Pfizer's brand name Viagra, sildenafil is currently available generically and even as a non-prescription over the counter medication in some countries [L5656].
Indications and Usage For the treatment of erectile dysfunction and to relieve symptoms of pulmonary arterial hypertension (PAH).
Marketing Status Prescription; Discontinued
ATC Code G04BE03
DrugBank ID DB00203
KEGG ID D08514
MeSH ID D000068677
PubChem ID 135398744
TTD Drug ID D0Z7ZM
NDC Product Code 17856-8100; 50268-717; 52817-340; 71335-1028; 45865-833; 70518-1216; 71205-473; 60219-1751; 0378-1658; 71610-256; 60687-416; 61919-826; 82647-211; 71335-1649; 50436-0776; 68001-176; 43063-676; 70748-132; 72789-103; 72789-098; 82647-210; 50436-1210; 31722-965; 42291-747; 72888-016; 27241-175; 59762-0033; 70748-133; 65162-351; 50090-5906; 33342-121; 70518-1844; 68071-2552; 46144-320; 31722-711; 63187-789; 43063-940; 31722-967; 50090-5415; 53002-1719; 68071-4854; 50090-3493; 52817-341; 71335-1437; 13668-188; 69543-419; 52817-295; 63187-813; 68071-4617; 31722-966; 68071-2608; 0378-1660; 71335-1088; 70518-2128; 68788-7680; 72865-105; 71335-0288; 69238-1574; 50090-5039; 65862-691; 76420-061; 71205-623; 65862-690; 0093-5343; 50090-5325; 31722-776; 68071-2566; 27241-067; 72888-017; 72189-069; 50090-5235; 68071-2537; 0378-1659; 70859-015; 68071-4517; 71205-267; 53002-2719; 71205-305; 0093-5342; 50090-4646; 72865-103; 63629-8129; 50090-1766; 52817-342; 68071-4744; 55700-677; 63629-5029; 71205-509; 27241-069; 31722-710; 43063-941; 43063-982; 63739-072; 71335-1005; 72888-015; 50090-5802; 71205-220; 0093-5341; 68788-7879; 71335-1963; 27241-124; 71610-271; 71610-237; 50436-0034; 68071-2213; 42291-748; 13668-186; 70518-1641; 68788-7974; 65862-689; 31722-709; 0093-5517; 13668-187; 71205-088; 71335-0969; 71335-1777; 50090-4644; 72888-018; 71335-1638; 68071-2217; 72865-101; 68788-7775; 43063-668; 72865-102; 68001-363; 70748-131; 63629-7833; 68071-5115; 65862-688; 68071-4674; 68071-4599; 61919-755; 68071-2072; 68071-2602; 71205-542; 82647-212; 72189-298; 0591-4050; 60219-1753; 27241-068; 50090-5236; 59762-2058; 42291-746; 71205-231; 63187-619; 71205-498; 70934-903; 60219-1752; 68071-5251
Synonyms Sildenafil Citrate | Citrate, Sildenafil | 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate | NCX-911 | NCX 911 | NCX911 | Revatio | Sildenafil | UK 92480-10 | UK 92480 10 | UK 9248010 | UK-92,480-10 | UK 92,480 10 | Homosildenafil | Hydroxyhomosildenafil | Viagra | Acetildenafil | Sildenafil Lactate | Lactate, Sildenafil | Sildenafil Nitrate | Nitrate, Sildenafil | Desmethyl Sildenafil | Sildenafil, Desmethyl | Desmethylsildenafil
Chemical Information
Molecular Formula C22H30N6O4S
CAS Registry Number 139755-83-2
SMILES CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aphonia19.19.01.002; 17.02.08.009; 22.02.05.0240.000554%
Appendicitis11.01.07.001; 07.19.01.0010.000554%
Arrhythmia02.03.02.0010.003599%Not Available
Arteriosclerosis24.04.02.0010.000144%Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.0110.000144%Not Available
Arteriospasm coronary24.04.04.005; 02.02.02.0050.000554%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.0010.001938%
Arthropathy15.01.01.0030.002215%Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Asthenia08.01.01.001--Not Available
Asthenopia06.01.01.002--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Atrial septal defect03.07.02.002; 02.04.02.009--Not Available
Atrioventricular block02.03.01.0020.000554%Not Available
Auditory disorder04.02.03.0020.000831%Not Available
Back disorder15.03.01.0140.001107%Not Available
Back pain15.03.04.005--
Balanoposthitis21.09.03.001--Not Available
Basal cell carcinoma23.08.02.001; 16.03.02.001--Not Available
Bladder pain20.02.02.001--Not Available
Blindness17.17.01.003; 06.02.02.0010.005260%Not Available
Blindness transient17.17.01.004; 06.02.02.0020.000554%Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.001107%Not Available
Blood bilirubin increased13.03.01.008--
Blood cholesterol increased13.12.01.002--
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.0010.000831%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 22 Pages